Eleftherios Diamandis

Eleftherios Diamandis's AcademicInfluence.com Rankings

Chemistry

#482

World Rank

#881

Historical Rank

chemistry Degrees

Eleftherios Diamandis

Biology

#1814

World Rank

#2946

Historical Rank

Biochemistry

#131

World Rank

#167

Historical Rank

biology Degrees

Download Badge

Chemistry
Biology

Why Is Eleftherios Diamandis Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Eleftherios Phedias Diamandis is a Greek Cypriot-Canadian biochemist who specializes in clinical chemistry. He is Professor & Head of Clinical Biochemistry in the Department of Laboratory Medicine and Pathobiology at the University of Toronto in Toronto, Ontario, Canada. He is also Division Head of Clinical Biochemistry at Mount Sinai Hospital and Biochemist-in-Chief at the University Health Network, both of which are also located in Toronto.

(See a Problem?)

Eleftherios Diamandis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. (1995) (915)
Cancer immunotherapy: the beginning of the end of cancer? (2016) (857)
Resveratrol: a molecule whose time has come? And gone? (1997) (805)
The biotin-(strept)avidin system: principles and applications in biotechnology. (1991) (740)
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies (2008) (695)
The new human tissue kallikrein gene family: structure, function, and association to disease. (2001) (674)
Wine as a biological fluid: History, production, and role in disease prevention (1997) (667)
Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool (2004) (663)
The emerging roles of human tissue kallikreins in cancer (2004) (626)
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. (2008) (603)
Novel therapeutic applications of cardiac glycosides (2008) (586)
Cancer-Associated Fibroblasts Drive the Progression of Metastasis through both Paracrine and Mechanical Pressure on Cancer Tissue (2012) (420)
Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. (2004) (418)
Potential markers that complement expression of CA125 in epithelial ovarian cancer. (2005) (362)
Distribution of 15 human kallikreins in tissues and biological fluids. (2007) (361)
Cancer biomarkers: can we turn recent failures into success? (2010) (347)
Human tissue kallikreins: physiologic roles and applications in cancer. (2004) (344)
Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? (2003) (330)
Wines and grape juices as modulators of platelet aggregation in healthy human subjects. (1996) (324)
Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens (2011) (283)
The New Human Kallikrein Gene Family: Implications in Carcinogenesis (2000) (279)
A Potential Role for Multiple Tissue Kallikrein Serine Proteases in Epidermal Desquamation* (2006) (262)
A comparison of the anticarcinogenic properties of four red wine polyphenols. (2002) (256)
Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. (1999) (253)
Human tissue kallikreins: a family of new cancer biomarkers. (2002) (243)
Proteinase-activated Receptors, Targets for Kallikrein Signaling* (2006) (240)
Method to assay the concentrations of phenolic constituents of biological interest in wines. (1996) (229)
Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers (1994) (228)
Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. (1998) (225)
Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. (1994) (216)
A Global Survey ofTrans-Resveratrol Concentrations in Commercial Wines (1995) (212)
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. (2003) (210)
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. (2010) (209)
Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. (2000) (201)
Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines (2007) (199)
Prostate-specific antigen in milk of lactating women. (1995) (198)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. (2010) (198)
Functional Roles of Human Kallikrein-related Peptidases* (2009) (198)
Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. (1992) (196)
Steroid hormone activity of flavonoids and related compounds (2000) (192)
Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. (2002) (190)
The cancer cell secretome: a good source for discovering biomarkers? (2010) (190)
Nonprostatic sources of prostate-specific antigen. (1997) (190)
Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. (2002) (185)
Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. (2000) (183)
New nomenclature for the human tissue kallikrein gene family. (2000) (181)
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. (1995) (179)
Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients (2007) (178)
B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. (2006) (176)
Prostate-specific Antigen: Its Usefulness in Clinical Medicine (1998) (174)
Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. (1996) (174)
The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. (2010) (171)
COVID-19: from an acute to chronic disease? Potential long-term health consequences (2020) (170)
A new europium chelate for protein labelling and time-resolved fluorometric applications. (1988) (170)
Human tissue kallikreins: the cancer biomarker family. (2007) (169)
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. (2003) (167)
The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? (2012) (165)
Emerging biomarkers for the diagnosis and prognosis of prostate cancer. (2008) (164)
Time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays. (1995) (161)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. (2008) (161)
Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. (2011) (157)
Parallel overexpression of seven kallikrein genes in ovarian cancer. (2003) (157)
Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer (2001) (156)
Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression* (2005) (153)
Proteomics Analysis of Human Amniotic Fluid *S (2007) (153)
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer (2010) (152)
Europium chelate labels in time-resolved fluorescence immunoassays and DNA hybridization assays. (1990) (151)
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. (2008) (150)
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection (2018) (150)
Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. (2002) (148)
Immunoassays with time-resolved fluorescence spectroscopy: Principles and applications (1988) (148)
Immunoassays with time-resolved fluorescence spectroscopy: principles and applications. (1988) (147)
The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. (2001) (147)
Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. (2003) (147)
New biological functions of prostate-specific antigen? (1995) (147)
Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications (2002) (147)
Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines* (2009) (144)
Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology (2010) (144)
Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. (1994) (143)
Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. (2003) (143)
Human tissue kallikrein gene family: applications in cancer. (2005) (143)
Prostate‐Specific antigen expression by various tumors (1995) (142)
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins (2006) (141)
Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. (2001) (140)
Seminal plasma as a diagnostic fluid for male reproductive system disorders (2014) (139)
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma (1995) (138)
Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. (1997) (137)
Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. (1996) (134)
Differential Diagnosis of Azoospermia with Proteomic Biomarkers ECM1 and TEX101 Quantified in Seminal Plasma (2013) (134)
Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. (1999) (134)
Proteomic analysis of human cervico-vaginal fluid. (2007) (133)
Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. (2000) (133)
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. (2004) (133)
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. (1999) (131)
The long journey of cancer biomarkers from the bench to the clinic. (2013) (131)
Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. (1995) (130)
Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. (2003) (129)
Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. (1993) (125)
Validation of new cancer biomarkers: a position statement from the European group on tumor markers. (2015) (124)
Molecular alterations during progression of prostate cancer to androgen independence. (2011) (123)
Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. (2001) (123)
Molecular Cloning of the Human Kallikrein 15 Gene (KLK15) (2001) (122)
Peptidomics for cancer diagnosis: present and future. (2006) (122)
Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls (2014) (120)
Human Tissue Kallikrein 5 Is a Member of a Proteolytic Cascade Pathway Involved in Seminal Clot Liquefaction and Potentially in Prostate Cancer Progression* (2006) (117)
Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. (2000) (116)
Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs) (2006) (116)
Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. (2001) (115)
Human kallikrein 10: a novel tumor marker for ovarian carcinoma? (2001) (114)
Prostate-specific antigen immunoreactivity in amniotic fluid. (1995) (114)
Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer (2014) (113)
Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. (1999) (113)
Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour Cells (2004) (112)
Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. (2005) (112)
Human kallikrein 6 as a biomarker of alzheimer's disease. (2000) (112)
Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. (2000) (110)
Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. (1995) (110)
Expression and Functional Characterization of the Cancer-related Serine Protease, Human Tissue Kallikrein 14* (2007) (109)
Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis (2006) (109)
Assay of resveratrol glucosides and isomers in wine by direct-injection high-performance liquid chromatography (1995) (109)
Absorption of trans-resveratrol in rats. (2001) (109)
Oral Contraceptive-induced Expression of Prostate-specific Antigen in the Female Breast (*) (1995) (108)
Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. (2008) (108)
Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers*S (2009) (108)
Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. (1998) (107)
Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. (1994) (107)
Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers (2011) (107)
Down-regulation of dicer expression in ovarian cancer tissues. (2010) (106)
Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. (2002) (105)
Verification of Male Infertility Biomarkers in Seminal Plasma by Multiplex Selected Reaction Monitoring Assay* (2011) (104)
Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma (2011) (104)
The serum concentration of the advanced glycation end-product Nε-(carboxymethyl)lysine is increased in uremia: Technical Note (1997) (102)
An automated "high-pressure" liquid-chromatographic assay for hemoglobin A1c. (1984) (102)
The New Kallikrein-like Gene, KLK-L2 (1999) (101)
Unleashing the therapeutic potential of human kallikrein-related serine proteases (2015) (101)
Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues (2003) (100)
A survey of alternative transcripts of human tissue kallikrein genes. (2005) (100)
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel (2008) (100)
Direct gas chromatographic-mass spectrometric method to assay cis-resveratrol in wines: preliminary survey of its concentration in commercial wines (1995) (100)
Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity--a controlled crossover trial. (2000) (98)
The world of resveratrol. (2001) (98)
The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - genomic characterization, mapping, tissue expression and hormonal regulation. (2000) (97)
Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. (2001) (96)
Kallikrein gene downregulation in breast cancer (2004) (95)
Proteomic Signatures of the Desmoplastic Invasion Front Reveal Collagen Type XII as a Marker of Myofibroblastic Differentiation During Colorectal Cancer Metastasis (2012) (95)
Identification and Characterization of KLK-L4, a New Kallikrein-like Gene That Appears to be Down-regulated in Breast Cancer Tissues* (2000) (95)
Human kallikrein 8, a novel biomarker for ovarian carcinoma. (2003) (94)
The Spectrum of Human Kallikrein 6 (Zyme/Protease M/Neurosin) Expression in Human Tissues as Assessed by Immunohistochemistry (2001) (93)
Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. (2008) (93)
Unleashing the therapeutic potential of human kallikrein-related serine proteases (2015) (93)
Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. (2001) (93)
Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. (2001) (93)
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells (2006) (93)
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. (1996) (92)
Expanded Human Tissue Kallikrein Family – A Novel Panel of Cancer Biomarkers (2002) (92)
Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer (2004) (91)
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. (2011) (91)
An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. (2003) (90)
Kallikrein-related Peptidase-8 (KLK8) Is an Active Serine Protease in Human Epidermis and Sweat and Is Involved in a Skin Barrier Proteolytic Cascade (2010) (89)
Multiple fluorescence labeling with europium chelators. Application to time-resolved fluoroimmunoassays. (1989) (88)
Laminin, gamma 2 (LAMC2): A Promising New Putative Pancreatic Cancer Biomarker Identified by Proteomic Analysis of Pancreatic Adenocarcinoma Tissues* (2013) (88)
Serum total and free prostate-specific antigen for breast cancer diagnosis in women. (2000) (88)
Prostate-specific antigen: a cancer fighter and a valuable messenger? (2000) (88)
Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker (2002) (87)
KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. (2000) (87)
Prostate-specific antigen in female serum, a potential new marker of androgen excess. (1997) (86)
The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast (2004) (86)
Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. (1999) (85)
Quantitative Analysis of Energy Metabolic Pathways in MCF-7 Breast Cancer Cells by Selected Reaction Monitoring Assay* (2012) (85)
Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. (2002) (85)
PSA and other tissue kallikreins for prostate cancer detection. (2007) (85)
Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. (1999) (85)
Time-resolved delayed luminescence image microscopy using an europium ion chelate complex. (1994) (85)
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. (2004) (83)
The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). (2000) (83)
Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions (2008) (83)
Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more (2006) (83)
Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks (2011) (83)
A multiresidue derivatization gas chromatographic assay for fifteen phenolic constituents with mass selective detection. (1997) (82)
Quantitative Proteomics Reveals That Enzymes of the Ketogenic Pathway Are Associated with Prostate Cancer Progression* (2013) (80)
Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. (2009) (80)
Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction? (2016) (78)
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue (2005) (78)
Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. (2002) (78)
Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue (2001) (78)
Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. (2003) (77)
Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. (2005) (76)
In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. (2004) (76)
Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. (2000) (76)
Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration (2008) (75)
"Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. (2008) (75)
Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. (2007) (75)
Role of kallikrein enzymes in the central nervous system. (2003) (75)
Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade (2008) (74)
Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. (1995) (74)
Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier (2010) (74)
Prostate-specific antigen in serum of women with breast cancer. (1995) (74)
Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. (2006) (74)
Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. (2003) (74)
Analysis of seminal plasma from patients with non-obstructive azoospermia and identification of candidate biomarkers of male infertility. (2012) (74)
DIRECT INJECTION GAS CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY FOR TRANS-RESVERATROL (1994) (73)
Differential N-glycosylation of Kallikrein 6 Derived from Ovarian Cancer Cells or the Central Nervous System* (2009) (73)
Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma (2003) (73)
Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. (2000) (73)
Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions (2000) (72)
A Derivatized Gas Chromatographic-Mass Spectrometric Method for the Analysis of Both Isomers of Resveratrol in Juice and Wine (1995) (72)
Proteomic Profiling of Androgen-independent Prostate Cancer Cell Lines Reveals a Role for Protein S during the Development of High Grade and Castration-resistant Prostate Cancer (2012) (72)
Immunofluorometric assay of prostaglandin D synthase in human tissue extracts and fluids. (1996) (72)
Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library (2002) (72)
Streptavidin-based macromolecular complex labeled with a europium chelator suitable for time-resolved fluorescence immunoassay applications (1990) (72)
Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. (2003) (72)
Down‐regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues (2002) (71)
The kallikrein world: an update on the human tissue kallikreins (2006) (71)
Insulin‐like growth factor–binding protein‐3 and breast cancer survival (1998) (71)
Human tissue kallikrein gene family: a rich source of novel disease biomarkers (2001) (70)
A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy (2007) (70)
Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. (2006) (70)
Tissue culture‐based breast cancer biomarker discovery platform (2008) (70)
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. (2003) (69)
Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. (2005) (69)
High throughput proteomic strategies for identifying tumour-associated antigens. (2007) (69)
Flavonoids and steroid hormone-dependent cancers. (2002) (69)
Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. (1995) (69)
Whole genome sequencing as a diagnostic test: challenges and opportunities. (2014) (69)
Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. (1999) (69)
Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues (2003) (69)
Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma (2003) (68)
Circulating antibodies against p53 protein in patients with ovarian carcinoma (1996) (68)
Toward an integrated pipeline for protein biomarker development. (2015) (68)
Cellular distribution of human tissue kallikreins: immunohistochemical localization (2006) (67)
Resveratrol Glucosides are Important Components of Commercial Wines (1996) (67)
B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. (2007) (67)
Human kallikrein gene 13 (KLK13) expression by quantitative RT–PCR: an independent indicator of favourable prognosis in breast cancer (2002) (67)
Downregulation of Human Kallikrein 10 (KLK10/NES1) by CpG Island Hypermethylation in Breast, Ovarian and Prostate Cancers (2005) (66)
The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. (2003) (66)
Human kallikrein 13 involvement in extracellular matrix degradation. (2004) (66)
Humoral immune response against p53 protein in patients with colorectal carcinoma (1997) (66)
Detection of prostate-specific antigen immunoreactivity in breast tumors (2004) (66)
The sweet and sour of serological glycoprotein tumor biomarker quantification (2013) (66)
Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs (2010) (66)
Digoxin immunoreactivity in cord and maternal serum and placental extracts. Partial characterization of immunoreactive substances by high-performance liquid chromatography and inhibition of Na+, K+-ATPase. (1985) (65)
Peptidomics of urine and other biofluids for cancer diagnostics. (2014) (65)
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance (2002) (65)
Genomic overview of serine proteases. (2003) (65)
Mass spectrometry: uncovering the cancer proteome for diagnostics. (2007) (65)
Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. (2010) (65)
Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. (1993) (64)
A Multiparametric Serum Kallikrein Panel for Diagnosis of Non–Small Cell Lung Carcinoma (2008) (64)
Structural characterization and mapping of the normal epithelial cell-specific 1 gene. (1998) (64)
Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. (2012) (64)
Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer (2008) (64)
Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers (2015) (63)
Streptavidin-polyvinylamine conjugates labeled with a europium chelate: applications in immunoassay, immunohistochemistry, and microarrays. (2000) (63)
New insights into the functional mechanisms and clinical applications of the kallikrein‐related peptidase family (2007) (63)
Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. (2006) (63)
Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. (2002) (62)
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer (1999) (62)
Relative Contributions of Polyphenolic Constituents to the Antioxidant Status of Wines: Development of a Predictive Model (1997) (62)
Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L. (1997) (62)
Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. (2012) (62)
Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer (2006) (62)
Expression of the kallikrein gene family in normal and Alzheimer's disease brain (2001) (61)
Human tissue kallikreins: from gene structure to function and clinical applications. (2005) (61)
Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. (1997) (61)
Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals (2006) (61)
Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression (2015) (61)
Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. (2003) (60)
Prostate-specific antigen in serum during the menstrual cycle. (1997) (60)
Strategies for discovering novel pancreatic cancer biomarkers. (2013) (60)
Enzymatic profiling of human kallikrein 14 using phage-display substrate technology (2005) (60)
The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer (2009) (59)
Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. (1997) (59)
Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. (2010) (59)
Quantitative analysis of kallikrein 15 gene expression in prostate tissue. (2003) (59)
Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. (2002) (59)
Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer (2009) (59)
Diabetes Induces Lysine Acetylation of Intermediary Metabolism Enzymes in the Kidney (2014) (59)
Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. (2001) (58)
Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas (2016) (58)
Multianalyte immunoassay based on spatially distinct fluorescent areas quantified by laser-excited solid-phase time-resolved fluorometry. (1992) (58)
Seminal plasma biochemical markers and their association with semen analysis findings. (1999) (57)
Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer (2005) (57)
Intron retention: a common splicing event within the human kallikrein gene family. (2005) (57)
Prognostic impact of CD68 and kallikrein 6 in human glioma. (2009) (57)
The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6) (2012) (57)
Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma (2008) (56)
Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis (2003) (56)
Salivary duct carcinoma secreting prostate-specific antigen. (1996) (56)
Human tissue kallikreins: a road under construction. (2007) (56)
Do wine polyphenols modulate p53 gene expression in human cancer cell lines? (2001) (55)
The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer (2003) (55)
Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9 (2013) (55)
Influences of viticultural and oenological factors on changes in cis‐ and trans‐resveratrol in commercial wines (1995) (55)
Kallikrein-related Peptidase 12 Hydrolyzes Matricellular Proteins of the CCN Family and Modifies Interactions of CCN1 and CCN5 with Growth Factors* (2011) (55)
Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines (2000) (55)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. (2008) (55)
Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. (2014) (54)
Biologic markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size (1999) (54)
Infection and Cancer: Revaluation of the Hygiene Hypothesis (2013) (54)
Quantification of eight tissue kallikreins in the stratum corneum and sweat. (2006) (54)
Characterization of androgen receptor and nuclear receptor co‐regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3 (2002) (54)
Immunofluorometry of choriogonadotropin by time-resolved fluorescence spectroscopy, with a new europium chelate as label. (1987) (54)
Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry (2014) (54)
Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer. (2001) (53)
Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. (2004) (53)
Wine: does the colour count? (1996) (53)
Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity (2009) (52)
Preclinical evaluation of a TEX101 protein ELISA test for the differential diagnosis of male infertility (2017) (52)
Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells. (2011) (52)
Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense (2008) (52)
Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin‐1 (2013) (52)
Ultrasensitive prostate-specific antigen assays and their clinical application. (1996) (52)
Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains (2013) (52)
Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. (2003) (52)
Prostaglandin D synthase concentration in cerebrospinal fluid and serum of patients with neurological disorders. (1997) (51)
Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. (2013) (51)
Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines (2004) (51)
Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. (2008) (51)
Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery (2012) (51)
Defining the extended substrate specificity of kallikrein 1-related peptidases (2007) (51)
Kallikrein-related peptidases (KLKs) and the hallmarks of cancer (2016) (51)
Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression (2014) (50)
Time-resolved fluorescence using a europium chelate of 4,7-bis-(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA). Labeling procedures and applications in immunoassays. (1988) (50)
Kallikreins as microRNA targets: an in silico and experimental-based analysis (2008) (50)
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer (2002) (50)
Mechanisms of Androgen-Independent Prostate Cancer (2014) (49)
Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. (1996) (49)
Major Role of Human KLK14 in Seminal Clot Liquefaction* (2008) (49)
Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines (2007) (48)
Revisiting the Complexity of the Ovarian Cancer Microenvironment—Clinical Implications for Treatment Strategies (2012) (48)
Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. (1999) (48)
Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. (2003) (48)
Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. (2018) (48)
Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. (2006) (48)
Flavonoids can block PSA production by breast and prostate cancer cell lines. (2002) (48)
Prostate specific antigen--new applications in breast and other cancers. (1996) (48)
Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis (2002) (47)
Serum human glandular kallikrein (hK2) and insulin‐like growth factor 1 (IGF‐1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA (2003) (47)
Collective migration of cancer‐associated fibroblasts is enhanced by overexpression of tight junction‐associated proteins claudin‐11 and occludin (2014) (47)
Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects (2007) (47)
Human Kallikrein 10 Expression in Normal Tissues by Immunohistochemistry (2002) (47)
Human tissue kallikreins and testicular cancer (2003) (47)
Ovarian cancer specific kallikrein profile in effusions. (2007) (46)
Ultrasensitive thyrotropin immunoassay based on enzymatically amplified time-resolved fluorescence with a terbium chelate. (1992) (46)
Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury (2015) (45)
Prostate-specific antigen production in the female breast: association with progesterone. (1998) (45)
Immunoreactive prostate‐specific antigen in lung tumors (1995) (45)
Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. (2010) (45)
Theranos phenomenon: promises and fallacies (2015) (45)
Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. (2004) (45)
Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies (2013) (44)
The periurethral glands do not significantly influence the serum prostate specific antigen concentration. (1996) (44)
Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma (2007) (44)
Three new serum markers for prostate cancer detection within a percent free PSA‐based artificial neural network (2006) (44)
Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines. (1998) (44)
Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer (2006) (44)
Nipple aspirate fluid proteome of healthy females and patients with breast cancer. (2010) (44)
Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. (2004) (43)
Purification and Characterization of Human Kallikrein 11, a Candidate Prostate and Ovarian Cancer Biomarker, from Seminal Plasma (2006) (43)
Analytical study of a new picrate-selective membrane electrode (1977) (43)
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer (2012) (43)
Time-resolved immunofluorometric assay of alpha-fetoprotein in serum and amniotic fluid, with a novel detection system. (1987) (43)
Kallikreins, steroid hormones and ovarian cancer: is there a link? (2002) (43)
Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer (2009) (42)
Multiple labeling and time-resolvable fluorophores. (1991) (42)
Seminal plasma lipocalin-type prostaglandin D synthase: a potential new marker for the diagnosis of obstructive azoospermia. (2008) (42)
The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. (2016) (42)
Identification and molecular characterization of a novel member of the siglec family (SIGLEC9). (2000) (42)
Proteomic and peptidomic analysis of human sweat with emphasis on proteolysis. (2017) (42)
Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays * (2016) (42)
Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma (2005) (42)
Europium and terbium chelators as candidate substrates for enzyme-labelled time-resolved fluorimetric immunoassays (1992) (42)
Human Kallikrein 13 Expression in Normal Tissues: An Immunohistochemical Study (2003) (42)
False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. (2014) (42)
Sequence and evolutionary analysis of the human trypsin subfamily of serine peptidases. (2004) (41)
Searching for new biomarkers of renal diseases through proteomics. (2012) (41)
Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. (2003) (41)
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. (2001) (41)
Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors (2003) (41)
In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. (2006) (41)
Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study (2009) (41)
p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. (2000) (41)
Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. (1996) (41)
Circulating Tumor DNA for Early Cancer Detection. (2018) (41)
Urinary adenosine excretion in type 1 diabetes. (2017) (41)
In silico Analysis of the Human Kallikrein Gene 6 (2004) (40)
Potential role of multiple members of the kallikrein-related peptidase family of serine proteases in activating latent TGFβ1 in semen (2010) (40)
Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients (2012) (40)
Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. (1996) (40)
Association of kallikrein expression in nipple aspirate fluid with breast cancer risk (2004) (40)
Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. (1999) (40)
How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. (2004) (40)
Direct measurement of serum free testosterone by ultrafiltration followed by liquid chromatography tandem mass spectrometry. (2010) (40)
New diagnostic applications and physiological functions of prostate specific antigen. (1995) (40)
Targeted Selected Reaction Monitoring Mass Spectrometric Immunoassay for Insulin-like Growth Factor 1 (2013) (39)
Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. (2001) (39)
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. (2011) (39)
Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers (2002) (39)
Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry (2012) (38)
Ultrasensitive Time-Resolved Fluorescence Method for α-Fetoprotein (1990) (38)
Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. (2010) (38)
Cloning and characterization of novel isoforms of the human kallikrein 6 gene. (2004) (38)
HUMAN KALLIKREINS: COMMON STRUCTURAL FEATURES, SEQUENCE ANALYSIS AND EVOLUTION (2003) (38)
Natriuretic peptides in heart failure. (2010) (38)
Nidogen-2: a new serum biomarker for ovarian cancer. (2010) (38)
Immunocapture-Selected Reaction Monitoring Screening Facilitates the Development of ELISA for the Measurement of Native TEX101 in Biological Fluids* (2015) (38)
The epigenetic basis for the aberrant expression of kallikreins in human cancers (2006) (37)
Molecular characterization of a Siglec8 variant containing cytoplasmic tyrosine-based motifs, and mapping of the Siglec8 gene. (2000) (37)
Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin. (2003) (37)
Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. (2001) (37)
Tissue kallikreins: new players in normal and abnormal cell growth? (2003) (37)
Laser-excited time-resolved solid-phase fluoroimmunoassays with the new europium chelate 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid as label. (1988) (37)
Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins (2006) (37)
Enzymatic properties of human kallikrein-related peptidase 12 (KLK12) (2007) (37)
Analytical methodology for immunoassays and DNA hybridization assays--current status and selected systems--critical review. (1990) (37)
Regional differences in resveratrol isomer concentrations of wines from various cultivars (1996) (36)
Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. (1998) (36)
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer (2016) (36)
Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection (2005) (36)
Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. (2004) (36)
Familial aggregation of diabetes and hypertension in a case-control study of colorectal neoplasia. (2002) (36)
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. (2013) (36)
Deciphering the ovarian cancer ascites fluid peptidome (2014) (36)
Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary (1994) (35)
Deciphering the peptidome of urine from ovarian cancer patients and healthy controls (2014) (35)
Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. (2000) (35)
Proteinases and their receptors in inflammatory arthritis: an overview (2018) (35)
The role of human tissue kallikreins 7 and 8 in intracranial malignancies (2006) (35)
Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. (1997) (35)
Potentiometric titration of organic cations with sodium tetraphenylborate and a liquid-membrane tetraphenylborate ion-selective electrode (1982) (35)
Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. (2007) (35)
An update on human and mouse glandular kallikreins. (2004) (35)
Rapid determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry and a split sample comparison with three automated immunoassays. (2009) (34)
Determination of an Angiotensin II-regulated Proteome in Primary Human Kidney Cells by Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC) (2013) (34)
Can circulating tumor DNA be used for direct and early stage cancer detection? (2017) (34)
Detection of prostate-specific antigen mRNA and protein in breast tumors. (1996) (34)
Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients (2020) (34)
The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. (2003) (34)
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. (2000) (34)
Comparative Evaluation of Four Methods for Assay of cis- and trans-Resveratrol (1997) (34)
The side effects of translational omics: overtesting, overdiagnosis, overtreatment (2016) (33)
Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. (2000) (33)
Proteinases as hormones: targets and mechanisms for proteolytic signaling (2008) (33)
Re: Serum proteomic patterns for detection of prostate cancer. (2003) (33)
Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. (2009) (33)
Prostate-specific antigen and lack of specificity for prostate cells (1995) (33)
Verification of a biomarker discovery approach for detection of Down syndrome in amniotic fluid via multiplex selected reaction monitoring (SRM) assay. (2011) (33)
Present and future of cancer biomarkers (2014) (33)
Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. (2003) (33)
Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. (2013) (33)
Frequency of expression of prostate-specific antigen mRNA in lung tumors. (1997) (33)
Proteomic patterns to identify ovarian cancer: 3 years on (2004) (33)
The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. (2000) (33)
Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer (2014) (33)
Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. (1996) (32)
Prostate cancer, prostate-specific antigen, and the polymerase chain reaction. (1995) (32)
Rapid and accurate determination of (CAG)n repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. (1999) (32)
Characterization of Human Kallikreins 6 and 10 in Ascites Fluid from Ovarian Cancer Patients (2006) (32)
Elevated levels of prostate-specific antigen in serum of women with fibroadenomas and breast cysts. (1997) (32)
Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. (1997) (32)
Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14 (2006) (31)
Elevated serum prostate-specific antigen levels in a woman with metastatic breast cancer. (2000) (31)
Identification of New Splice Variants and Differential Expression of the Human Kallikrein 10 Gene, a Candidate Cancer Biomarker (2005) (31)
Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome (2013) (31)
Mining the malignant ascites proteome for pancreatic cancer biomarkers (2011) (31)
Complex formation between human kallikrein 13 and serum protease inhibitors. (2004) (31)
Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. (2012) (31)
Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. (2008) (31)
Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid (2010) (31)
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status (2006) (31)
Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. (2002) (31)
High-Throughput Screening Identifies Cardiac Glycosides as Potent Inhibitors of Human Tissue Kallikrein Expression: Implications for Cancer Therapies (2008) (31)
Activation and enzymatic characterization of recombinant human kallikrein 8 (2006) (31)
Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease (2012) (31)
Time-resolved fluoroimmunoassay of cortisol in serum with a europium chelate as label. (1988) (31)
The hundred person wellness project and Google’s baseline study: medical revolution or unnecessary and potentially harmful over-testing? (2015) (31)
Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays. (1999) (31)
The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines (1999) (31)
Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer (2001) (30)
Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer’s disease progression (2018) (30)
Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids (2008) (30)
Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. (2002) (30)
TA Repeat Polymorphism of the 5α-Reductase Gene and Breast Cancer (2000) (30)
Towards identification of true cancer biomarkers (2014) (30)
Construction of ion-selective electrodes for chlorpromazine, amitriptyline, propantheline and meperidine: analytical study and application to pharmaceutical analysis. (1985) (29)
Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells* (2016) (29)
Catalytic determination of selenium with a picrate-selective electrode (1981) (29)
A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology (2008) (29)
Intracellular Signaling Pathways Regulate Hormone-Dependent Kallikrein Gene Expression (2008) (29)
Fascin-1 is a novel biomarker of aggressiveness in some carcinomas (2013) (29)
Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes. (2002) (29)
Polyvinylamine-streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time resolved fluorometric applications. (2000) (29)
Nucleic acid detection immunoassay for prostate-specific antigen based on immuno-PCR methodology. (2012) (29)
Potentiometric determination of nicotine in tobacco products with a nicotine-sensitive liquid membrane electrode (1981) (29)
Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA) (2008) (29)
[Human kallikrein 13 expression in salivary gland tumors]. (2006) (29)
Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines (2008) (29)
The plasma peptides of ovarian cancer (2018) (28)
Identification of novel biomarkers of brain damage in patients with hemorrhagic stroke by integrating bioinformatics and mass spectrometry-based proteomics. (2014) (28)
Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients (2007) (28)
The human kallikrein gene family: new biomarkers for ovarian cancer. (2009) (28)
Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids (2013) (28)
Sequencing with microarray technology--a powerful new tool for molecular diagnostics. (2000) (27)
Human Kallikrein 8 Expression in Salivary Gland Tumors (2008) (27)
Proteomic and Mass Spectrometry Technologies for Biomarker Discovery (2013) (27)
Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer (2001) (27)
Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer (2016) (27)
Differential Expression of a Human Kallikrein 5 (KLK5) Splice Variant in Ovarian and Prostate Cancer (2004) (27)
Coupling proteomics and transcriptomics in the quest of subtype‐specific proteins in breast cancer (2013) (27)
Antibodies to the p53 tumor suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. (1992) (27)
Development of a multiplex selected reaction monitoring assay for quantification of biochemical markers of down syndrome in amniotic fluid samples. (2012) (27)
Cobalt and chromium measurement in patients with metal hip prostheses. (2013) (27)
Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research (2014) (27)
Genomic instability and copy‐number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas (2011) (27)
NOVEL SERUM BIOMARKERS DIFFERENTIATE PSORIATIC ARTHRITIS FROM PSORIASIS WITHOUT PSORIATIC ARTHRITIS (2017) (27)
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers (2014) (26)
Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies (2013) (26)
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma (1999) (26)
The Role of Molecular Forms of Prostate-Specific Antigen (PSA or hK3) and of Human Glandular Kallikrein 2 (hK2) in the Diagnosis and Monitoring of Prostate Cancer and in Extra-Prostatic Disease (2001) (26)
Identification and quantification of peptides and proteins secreted from prostate epithelial cells by unbiased liquid chromatography tandem mass spectrometry using goodness of fit and analysis of variance. (2012) (26)
Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network (2006) (26)
Human Kallikrein 6 Expression in Salivary Gland Tumors (2006) (26)
In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers. (2014) (26)
Quantification of nucleic acids on nitrocellulose membranes with time-resolved fluorometry. (1991) (26)
Serum prostate-specific antigen measured in children from birth to age 18 years. (1996) (26)
Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility (2009) (26)
Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot Study (2006) (26)
Proteomic signatures of angiogenesis in androgen‐independent prostate cancer (2014) (26)
Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis (2013) (25)
Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men (2007) (25)
An integrated proteomic and peptidomic assessment of the normal human urinome (2017) (25)
OvaCheck: doubts voiced soon after publication (2004) (25)
An overview of mental health during the COVID-19 pandemic (2021) (25)
Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics* (2015) (25)
Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors (2012) (25)
Potentiometric determination of some common alkaloids with a picrate-selective electrode (1981) (25)
Q & A # 13 Pheochromocytoma (2013) (25)
Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer (2001) (24)
Immunoassay interference: a relatively rare but still important problem. (2004) (24)
From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. (2012) (24)
Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers (2018) (24)
Differential proteomic analysis of bronchoalveolar lavage fluid from lung transplant patients with and without chronic graft dysfunction. (2012) (24)
Putative functions of tissue kallikrein-related peptidases in vaginal fluid (2016) (24)
Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts (2014) (24)
Immunohistochemical Localization of Human Kallikreins 6 and 10 in Pancreatic Islets (2002) (24)
Ovarian cancer biomarkers: current state and future implications from high-throughput technologies. (2014) (24)
Variable selectivity of the Hitachi chemistry analyzer chloride ion-selective electrode toward interfering ions. (1994) (24)
Autoantibodies against the p53 tumor suppressor gene product quantified in cancer patient serum with time-resolved immunofluorometry (1993) (23)
The search for new prostate cancer biomarkers continues. (2009) (23)
Performance evaluation of Siemens ADVIA Centaur and Roche MODULAR Analytics E170 Total 25-OH Vitamin D assays. (2012) (23)
Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. (2001) (23)
p53 protein is absent from the serum of patients with lung cancer. (1996) (23)
High Expression of KLK14 in Prostatic Adenocarcinoma Is Associated with Elevated Risk of Prostate-Specific Antigen Relapse (2008) (23)
Quantification of polymerase chain reaction products in agarose gels with a fluorescent europium chelate as label and time-resolved fluorescence spectroscopy. (1993) (23)
Genistein: a potent natural antiandrogen. (2000) (23)
Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. (2003) (23)
Prostate cancer screening with prostate-specific antigen testing: more answers or more confusion? (2010) (23)
Kallikrein 6 as a Serum Prognostic Marker in Patients with Aneurysmal Subarachnoid Hemorrhage (2012) (23)
Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer (2015) (23)
Proteogenomics: Opportunities and Caveats. (2016) (23)
Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14 (2013) (23)
Conquering cancer in our lifetime: new diagnostic and therapeutic trends. (2013) (23)
Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. (2007) (23)
Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion‐exchange chromatography coupled to ELISA and identification by mass spectrometry (2012) (22)
Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. (2014) (22)
Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis (2009) (22)
Prostate specific antigen — a new constituent of breast cyst fluid (2005) (22)
Preliminary examination of time-resolved fluorometry for protein array applications. (2000) (22)
What is wrong with clinical proteomics? (2014) (22)
Is prostate-specific antigen present in female serum? (1998) (22)
Integrating meta-analysis of microarray data and targeted proteomics for biomarker identification: application in breast cancer. (2014) (22)
Binding studies using ion-selective electrodes. Examination of the picrate-albumin interaction as a model system. (1990) (22)
POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma? (2007) (22)
Time-Resolved Fluorescence (2000) (22)
Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter (2000) (22)
Biomarkers for the diagnosis of new and recurrent prostate cancer. (2012) (22)
Quantitative western blot analysis and spot immunodetection using time-resolved fluorometry. (1992) (22)
Prostate-specific antigen in cerebrospinal fluid. (1997) (21)
Detection of prostate-specific antigen mRNA by reverse transcription polymerase chain reaction and time-resolved fluorometry. (1995) (21)
The Journal Impact Factor is under attack – use the CAPCI factor instead (2017) (21)
Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. (2000) (21)
Does prostate cancer start at puberty? (1996) (21)
Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration. (2013) (21)
Synovial fluid proteomics in the pursuit of arthritis mediators: An evolving field of novel biomarker discovery (2017) (21)
Towards personalized tumor markers (2017) (21)
New 11β-aryl-substituted steroids exhibit both progestational and antiprogestational activity (1998) (21)
Comparison of protein expression lists from mass spectrometry of human blood fluids using exact peptide sequences versus BLAST (2006) (21)
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. (2015) (21)
Potentiometric titration of pharmaceutical compounds in formulations with sodium tetraphenylborate (1983) (21)
Molecular cloning of a novel human gene on chromosome 4p11 by immunoscreening of an ovarian carcinoma cDNA library. (2001) (21)
Kinetic potentiometric determination of creatinine in urine with a picrate-ion-selective electrode (1977) (21)
Are Antibodies to Carbonic Anhydrase II Specific for Anti-Mitochondrial Antibody-Negative Primary Biliary Cirrhosis? (2000) (21)
The Kallikrein Gene 5 Splice Variant 2 Is a New Biomarker for Breast and Ovarian Cancer (2004) (21)
Cloning of a kallikrein pseudogene. (2004) (21)
Oncopeptidomics: a useful approach for cancer diagnosis? (2007) (21)
An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. (2016) (21)
Construction and analytical applications of an improved liquid-membrane electrode for salicylate (1984) (21)
Delineating the synovial fluid proteome: Recent advancements and ongoing challenges in biomarker research (2013) (20)
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. (2006) (20)
Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker for Nasopharyngeal Carcinoma (2004) (20)
Androgen receptor: A promising therapeutic target in breast cancer (2019) (20)
Short tandem repeat polymorphism and cancer risk: influence of laboratory analysis on epidemiologic findings. (2004) (20)
Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease (1999) (20)
Collagen type XII and versican are present in the early stages of cartilage tissue formation by both redifferentating passaged and primary chondrocytes. (2015) (20)
Comparative Proteomics of Ovarian Cancer Aggregate Formation Reveals an Increased Expression of Calcium-activated Chloride Channel Regulator 1 (CLCA1)* (2015) (20)
A renin-ssance in primary aldosteronism testing: obstacles and opportunities for screening, diagnosis, and management. (2015) (20)
Association between Echinococcus granulosus infection and cancer risk – a pilot study in Cyprus (2016) (20)
New approaches for detecting cancer with circulating cell-free DNA (2019) (20)
Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung (2008) (20)
Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring (2016) (20)
KLK15 is a prognostic marker for progression‐free survival in patients with radical prostatectomy (2010) (19)
Is early detection of cancer with circulating biomarkers feasible? (2013) (19)
Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14 (2012) (19)
Novel biomarkers for acute myocardial infarction: is microRNA the new kid on the block? (2014) (19)
Exon 5 of the p53 gene is a target for deletions in ovarian cancer. (1998) (19)
Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. (1995) (19)
Models of neoplasia and their diagnostic implications: a historical perspective. (1993) (19)
Prognostic significance of multiple kallikreins in high-grade astrocytoma (2015) (19)
Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer (2013) (19)
Rapid sequencing of the p53 gene with a new automated DNA sequencer. (1998) (19)
Publishing costs: Peer review as a business transaction (2015) (19)
Peptidomic Analysis of Urine from Youths with Early Type 1 Diabetes Reveals Novel Bioactivity of Uromodulin Peptides In Vitro* (2019) (19)
Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer (2008) (19)
Prostaglandin D2 synthase: a component of human amniotic fluid and its association with fetal abnormalities. (1996) (19)
Antibody tests for COVID-19: drawing attention to the importance of analytical specificity (2020) (19)
Cockayne syndrome in three sisters with varying clinical presentation. (2002) (19)
Changes in serum carbohydrate‐deficient transferrin and gammaglutamyl transferase after moderate wine consumption in healthy males (1998) (19)
The plasma peptidome (2018) (19)
An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines (2008) (18)
Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells (2003) (18)
Androgens act synergistically to enhance estrogen‐induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor (2008) (18)
Preeclampsia: an old disease with new tools for better diagnosis and risk management. (2015) (18)
Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display (2008) (18)
Automation of molecular diagnostics. (1996) (18)
Immunofluorometric assay of pepsinogen C and preliminary clinical applications. (1997) (18)
Accuracy of testosterone concentrations in compounded testosterone products. (2015) (18)
A new era in prenatal diagnosis: the use of cell-free fetal DNA in maternal circulation for detection of chromosomal aneuploidies. (2013) (18)
Discovery of a Human Testis-specific Protein Complex TEX101-DPEP3 and Selection of Its Disrupting Antibodies* (2018) (18)
Cartilage tissue enhances proteoglycan retention by nucleus pulposus cells in vitro. (2010) (18)
Searching for prognostic biomarkers for small renal masses in the urinary proteome (2020) (18)
Molecular characterization, tissue expression, and mapping of a novel Siglec-like gene (SLG2) with three splice variants. (2001) (18)
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease (2018) (18)
Frequent detection of mutations in the 5' flanking region of the prostate-specific antigen gene in female breast cancer. (1997) (18)
An Emerging Role of TEX101 Protein as a Male Infertility Biomarker (2014) (18)
Oncogenes and tumor suppressor genes: new biochemical tests. (1992) (18)
Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients* (2019) (17)
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination (1999) (17)
Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients (1998) (17)
Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. (1995) (17)
Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification (2021) (17)
Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. (2000) (17)
Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer (2012) (16)
Human tissue kallikrein 9: production of recombinant proteins and specific antibodies (2006) (16)
Targeted Mass Spectrometry-Based Assays for Relative Quantification of 30 Brain-Related Proteins and Their Clinical Applications. (2018) (16)
Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker (2016) (16)
A Spectrum of Views on Clinical Mass Spectrometry. (2016) (16)
Alzheimer disease: advances in pathogenesis, diagnosis, and therapy. (2011) (16)
Putative kallikrein substrates and their (patho)biological functions (2014) (16)
Abstract 4119: High-throughput proteomics reveals that enzymes of the ketogenic pathway are upregulated during prostate cancer progression (2012) (16)
Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA (2020) (16)
Ion-selective electrodes for the H2-receptor antagonists cimetidine and ranitidine. (1987) (16)
Validation of breast cancer biomarkers identified by mass spectrometry. (2006) (16)
Quantitative analysis of p53 protein in non‐small cell lung cancer and its prognostic value (1998) (16)
Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers? (2018) (16)
The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry (2018) (16)
Discovery of Antimicrobial Peptides in Cervical‐Vaginal Fluid from Healthy Nonpregnant Women via an Integrated Proteome and Peptidome Analysis (2017) (15)
Quality of the scientific literature: all that glitters is not gold. (2006) (15)
An alternatively spliced variant of KLK4 expressed in prostatic tissue. (2000) (15)
Time-resolved immunofluorometric assay of p53 protein. (1995) (15)
Prognostic Urinary miRNAs for the Assessment of Small Renal Masses. (2019) (15)
Sequence analysis of the human kallikrein gene locus identifies a unique polymorphic minisatellite element. (2001) (15)
Application of proteomics to prenatal screening and diagnosis for aneuploidies (2011) (15)
Comparison of methods to examine the endogenous peptides of fetal calf serum (2006) (15)
Clinical applications of the p53 tumor suppressor gene. (1995) (15)
Construction and analytical applications of liquid-membrane electrodes for atropine and novatropine (1981) (15)
Alzheimer Disease Pathogenesis: The Role of Autoimmunity. (2020) (15)
Re: diagnostic potential of serum proteomic patterns in prostate cancer. (2004) (15)
Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. (1998) (15)
Protein quantification by mass spectrometry: is it ready for prime time? (2009) (15)
A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization (2017) (15)
Mutations in normal tissues—some diagnostic and clinical implications (2020) (15)
Flow-through electrode unit for liquid membrane electrodes (1980) (15)
Human kallikrein‐related peptidase 12: Antibody generation and immunohistochemical localization in prostatic tissues (2007) (15)
Effectiveness of the Risk of Malignancy Index and the Risk of Ovarian Malignancy Algorithm in a Cohort of Women With Ovarian Cancer: Does Histotype and Stage Matter? (2015) (14)
Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: impact on kallikrein 6 protein expression. (2013) (14)
Effect of testosterone administration on serum and urine kallikrein concentrations in female-to-male transsexuals. (2006) (14)
The Role of Procalcitonin in Diagnosis of Sepsis and Antibiotic Stewardship: Opportunities and Challenges. (2017) (14)
Kinetic potentiometric determination of creatinine in serum with a picrate ion-selective membrane electrode. (1981) (14)
Detection techniques for immunoassay and DNA probing applications. (1990) (14)
The bifacial role of helminths in cancer: Involvement of immune and non-immune mechanisms (2014) (14)
Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. (2000) (14)
Molecular Cloning of a New Gene Which Is Differentially Expressed in Breast and Prostate Cancers (2004) (14)
Early prostate cancer antigen-2: a controversial prostate cancer biomarker? (2010) (14)
Cloning and molecular characterization of two splice variants of a new putative member of the Siglec-3-like subgroup of Siglecs. (2001) (14)
Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction (2017) (14)
KLK 12 Is a Novel Serine Protease and a New Member of the Human Kallikrein Gene Family — Differential Expression in Breast Cancer (2000) (14)
Use of MALDI-TOF for diagnosis of microbial infections. (2013) (14)
Identification of TEX101-associated Proteins Through Proteomic Measurement of Human Spermatozoa Homozygous for the Missense Variant rs35033974* (2018) (14)
3 – THEORY OF IMMUNOASSAYS (1996) (14)
Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer (2017) (14)
Selective determination of urinary free cortisol by liquid chromatography after solid-state extraction. (1988) (14)
OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery (2014) (13)
Can a Broad Molecular Screen Based on Circulating Tumor DNA Aid in Early Cancer Detection? (2020) (13)
The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets (2020) (13)
Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? (2021) (13)
Clinical applications of tumor suppressor genes and oncogenes in cancer. (1997) (13)
A new enzyme-linked immunosorbent assay (ELISA) for human free and bound kallikrein 9 (2017) (13)
Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease (2019) (13)
Continuous-flow determination of reducing sugars and sucrose in natural and industrial products with periodate oxidation and a periodate-sensitive flow-through electrode. (1982) (13)
Major milestones in translational oncology (2016) (13)
P4 Medicine or O4 Medicine? Hippocrates Provides the Answer. (2019) (13)
Proteomic analysis of cancer and mesothelial cells reveals an increase in Mucin 5AC during ovarian cancer and peritoneal interaction. (2014) (13)
Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. (2017) (13)
Sensitive, rapid procedure for time-resolved immunofluorometry of lutropin. (1988) (13)
Maternal serum prostate‐specific antigen and Down syndrome in the first and second trimesters of pregnancy (1999) (13)
Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry (2019) (13)
Technology-driven diagnostics: From smart doctor to smartphone (2016) (12)
Putative autoantibodies in the cerebrospinal fluid of Alzheimer’s disease patients (2019) (12)
Journal Impact Factor: it will go away soon (2009) (12)
Time‐resolved fluorometry in nucleic acid hybridization and Western blotting techniques (1993) (12)
The plasma peptides of breast versus ovarian cancer (2019) (12)
Expression of the prostate specific antigen gene by lung tissue. (1997) (12)
Flow-through units for solid-state, liquid and PVC matrix membrane ion-selective electrodes to minimise streaming potentials (1987) (12)
Dissolution studies of drug formulations using ion-selective electrodes as sensors in an air-segmented continuous flow analyzer. (1987) (12)
Continuous-flow serum albumin determination by reaction with picrate ions, with use of a flow-through picrate ion electrode. (1981) (12)
Circulating cancer cells and their clinical applications. (2011) (12)
Aberrant expression of kallikrein‐related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion (2017) (12)
B 7-H 4 is over-expressed in early-stage ovarian cancer and is independent of CA 125 expression (2007) (12)
A repository for “rare” tumor markers? (2014) (12)
The emerging landscape of scientific publishing. (2017) (12)
A proteome-wide immuno-mass spectrometric identification of serum autoantibodies (2019) (12)
Potentiometric titration of sulphate, sulphite and dithionate mixtures, with use of a lead ion-selective electrode. (1983) (12)
CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer. (2012) (11)
How to reduce scientific irreproducibility: the 5-year reflection (2017) (11)
Detection of immunoglobulins G and M to rubella virus by time-resolved immunofluorometry (1990) (11)
Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET (2019) (11)
Biochemical pathways mediated by KLK6 protease in breast cancer (2019) (11)
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. (2006) (11)
Delineating monoclonal antibody specificity by mass spectrometry. (2015) (11)
Theranos phenomenon − part 2 (2015) (11)
Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass. (2019) (11)
Digoxin immunoassay with monoclonal and polyclonal antibodies using time-resolved fluorometry. (1989) (11)
A Word of Caution on New and Revolutionary Diagnostic Tests. (2016) (11)
Next-generation sequencing: a new revolution in molecular diagnostics? (2009) (11)
Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study (2020) (11)
Ethnic variation in kallikrein expression in nipple aspirate fluid (2002) (11)
Human Kallikrein 14 (Klk14) Expression in Salivary Gland Tumors (2010) (11)
Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship? (2019) (11)
Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases (2018) (11)
Titrimetric determination of iodide, hexacyanoferrate(ii), thiourea, cationic surfactants, and of picrate with a picrate ion-selective electrode (1980) (11)
Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm (2021) (11)
Genomic Organization of the Human Kallikrein Gene (2000) (11)
A multi-cancer detection test: focus on the positive predictive value. (2020) (11)
Direct-to-Consumer Testing. (2017) (11)
Identification and characterization of a novel human testis-specific kinase substrate gene which is downregulated in testicular tumors. (2001) (11)
Autoimmune diseases: early diagnosis and new treatment strategies. (2012) (10)
Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids. (2011) (10)
Benign and malignant scientific irreproducibility. (2018) (10)
Automated stopped-flow analyser in clinical chemistry: determination of albumin with bromcresol green and purple. (1985) (10)
Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome. (2016) (10)
Simpson’s paradox in proof-of-concept studies (2019) (10)
Kinetic study of the reaction between trinitrobenzenesulfonic acid and amino acids with a trinitrobenzenesulfonate ion-selective electrode. (1986) (10)
Circulating tumor DNA for personalized lung cancer monitoring (2017) (10)
HtrA3 stromal expression is correlated with tumor budding in stage II colorectal cancer. (2017) (10)
Assessment of serum prostate specific antigen in childhood (2004) (10)
Abstract 5075: An integratedin silicoand proteomic approach towards the identification of novel cancer biomarkers based on tissue specificity (2011) (10)
More discussion on journal impact factor (2013) (10)
A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (KLK) locus (2007) (10)
Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection (2020) (10)
Liquid chromatography of glycated hemobglobins with the Daiichi HA-8110 automated analyzer. (1984) (10)
Drug-Resistant Bacteremia after Fecal Microbiota Transplant. (2020) (10)
Nonprostatic sources of prostate-specific antigen : Prostate-specific antigen: the best prostatic tumor marker (1997) (10)
TA repeat polymorphism of the 5alpha-reductase gene and breast cancer. (2000) (10)
Prostate-Specific Antigen as a Marker of Hyperandrogenism in Women and Its Implications for Antidoping. (2016) (10)
Are cardiovascular and sympathoadrenal effects of human "new pressor protein" preparations attributable to human coagulation beta-FXIIa? (2004) (10)
Identificacion and assay of Trihydroxystilbenes in wine and their biological properties (1997) (10)
Prostate-specific antigen levels in nipple aspirate fluid. (2001) (9)
Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS) (2017) (9)
Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer (2018) (9)
Ultrasensitive Time-ResolvedImmunofluorometric Assayof Prostate-Specific Antigen in Serumand Preliminary ClinicalStudies (1993) (9)
Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2 (2021) (9)
Kallikrein-related peptidase 10 expression in salivary gland tissues and tumours (2012) (9)
Pancreatic cancer. (2013) (9)
Stable flow-induced expression of KLK10 inhibits endothelial inflammation and atherosclerosis (2021) (9)
1 – PAST, PRESENT, AND FUTURE OF IMMUNOASSAYS (1996) (9)
Collecting duct carcinoma associated with oncocytoma. (2005) (9)
Stable Isotope Labeling with Amino Acids (SILAC)-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male Sex Hormones and Impaired Energy Metabolism in Diabetic Kidney Disease* (2017) (9)
Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases (2017) (9)
The current peer review system is unsustainable-awaken the paid reviewer force! (2017) (9)
Analytical Study of New Creatininium and Tetramethyl-ammonium Cation Selective Membrane Electrodes (1980) (9)
Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time? (2015) (9)
Identification of deletions and insertions in the p53 gene using multiplex PCR and high‐resolution fragment analysis: Application to breast and ovarian tumors (1998) (9)
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma (2006) (9)
Animal olfactory detection of disease: promises and pitfalls. (2014) (9)
Biomarker validation is still the bottleneck in biomarker research (2012) (9)
Can Grail find the trail to early cancer detection? (2018) (9)
Effect of Incubation Time and Temperature on the Interference of Digoxin‐like Immunoreactive Substances in Digoxin Immunoassays (1987) (9)
Sensitive time-resolved immunofluorometric assay of thyrotropin in serum. (1989) (9)
6 Clinical Relevance of Kallikrein-related Peptidases in Breast Cancer (2012) (9)
Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer. (2017) (9)
Radioimmunoassay of Digoxin in Serum Using Monoclonal Antibodies and Assessment of Interference by Digoxin‐Like Immunoreactive Substances (1990) (8)
Nobelitis: a common disease among Nobel laureates? (2013) (8)
Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer specimens. (1997) (8)
Discovery of novel plasma biomarker ratios to discriminate traumatic brain injury (2019) (8)
Ectopic pregnancy. (2012) (8)
Prostate-Specific Antigen or Human Kallikrein 3? (1998) (8)
Cloning, physical mapping and structural characterization of the human alpha(A)-adaptin gene. (2002) (8)
Make researchers revisit past publications to improve reproducibility (2017) (8)
Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy (2014) (8)
Prostate specific antigen production by breast tumors after induction with oral contraceptives. (1998) (8)
Down-regulation of the normal epithelial cell-specific 1 (NES1) gene is associated with unfavorable outcome of prostate cancer. (2000) (8)
Human kallikrein 14 (KLK14) expression in salivary gland tumors. (2010) (8)
The proteomic revolution in laboratory medicine. (2013) (8)
Colorectal , and Ovarian Cancer Screening Trial Specimens Ovarian Cancer Biomarker Performance in Prostate , Lung , Updated (2011) (8)
Genomic profiling for copy number changes in plasma of ovarian cancer patients – a new era for cancer diagnostics? (2016) (8)
CRISPR-Cas9 System: Opportunities and Concerns. (2016) (8)
The Use of Targeted Therapies for Precision Medicine in Oncology. (2016) (8)
A sensitive time-resolved immunofluorometric assay of ferritin in serum with monoclonal antibodies. (1988) (8)
Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation (2017) (8)
Theranos phenomenon – part 4: Theranos at an International Conference (2016) (8)
Ultrasensitive determination of europium using microsecond time-resolved spectrofluorimetry (1991) (8)
Biochemical and functional characterization of the human tissue kallikrein 9. (2017) (8)
Theranos promises a new era of preventive health care - but where's the physician? (2015) (7)
Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. (1999) (7)
Is ICI 182,780 an antiprogestin in addition to being an antiestrogen? (2000) (7)
The New Kallikrein-like Gene , KLK-L 2 MOLECULAR CHARACTERIZATION , MAPPING , TISSUE EXPRESSION , AND HORMONAL (1999) (7)
Theranos phenomenon – part 3 (2016) (7)
Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value (2019) (7)
Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer. (2018) (7)
olecular Characterization of a Siglec 8 Variant ontaining Cytoplasmic Tyrosine-Based Motifs , nd Mapping of the Siglec 8 Gene (2000) (7)
Time-resolved immunofluorometric assay of human pancreatic isoamylase in serum, with use of two monoclonal antibodies. (1989) (7)
Cancer genomes. (2010) (7)
BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. (1997) (7)
An enzymatic method for measuring serum mannitol and its use in hemodialysis patients. (1992) (7)
Study of kallikrein-related peptidase 6 (KLK6) and its complex with α1-antitrypsin in biological fluids (2017) (7)
Assessment of p53 overexpression by non‐immunohistochemical methods (1995) (7)
Steroid hormone effects of natural products and nutraceuticals (2001) (7)
Epigenomics-based diagnostics. (2010) (6)
Sensitive time-resolved fluorescence immunoassay of somatotropin in serum. (1990) (6)
Recent advances in cancer biomarkers. (2004) (6)
Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors. (2006) (6)
Ion-selective electrodes for the determination of ionisation constants of sparingly soluble organic bases in aqueous solutions: applications to chlorpromazine and amitriptyline (1985) (6)
Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses (2019) (6)
Total calcium and magnesium determined in serum with an automated stopped-flow analyzer. (1982) (6)
Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines (2007) (6)
Advances in Brief Prostase / KLK-L 1 Is a New Member of the Human Kallikrein Gene Family , Is Expressed in Prostate and Breast Tissues , and Is Hormonally Regulated (1999) (6)
Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer (2019) (6)
Human kallikrein 10 in surgically removed human pituitary adenomas (2014) (6)
A Simple Time-Resolved Fluoroimmunoassay of Total Thyroxine in Serum (1989) (6)
Identification of TEX101-associated Proteins Through Proteomic Measurement of Human Spermatozoa Homozygous for the Missense Variant rs35033974. (2019) (6)
Laboratory Medicine Practice Guidelines Use of Tumor Markers in Liver , Bladder , Cervical , and Gastric Cancers (2010) (6)
Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with antiandrogens and estrogens. (2006) (6)
New diagnostic applications of prostate-specific antigen. (1997) (6)
The democratization of scientific publishing (2019) (6)
lavonoids and steroid hormone-dependent cancers (2002) (6)
Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1 (2020) (6)
Kallikrein-related peptidases protein expression in lymphoid tissues suggests potential implications in immune response. (2020) (6)
Identification of exon 1 of prostase/KLK-L1 gene. (2000) (6)
Titrimetric determination of thiourea and silver with a picrate ion selective electrode (1977) (6)
Ultrasensitive time-resolved fluorescence method for alpha-fetoprotein. (1990) (6)
The role of ubiquitin-binding domains in human pathophysiology (2014) (6)
Electronic field effect detection of SARS-CoV-2 N-protein before the onset of symptoms (2022) (5)
CSF neurofilament light may predict progression from amnestic mild cognitive impairment to Alzheimer's disease dementia (2021) (5)
Cancer Diagnostics: Discovery and Clinical Applications—Introduction (2002) (5)
A definitive gas-chromatographic mass-spectrometric assay for resveratrol suitable for industrial and biological samples (1993) (5)
Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients. (2019) (5)
Proteomic Profiling of the Human Tissue and Biological Fluid Proteome. (2020) (5)
An enzyme-linked immuno-mass spectrometric assay with the substrate adenosine monophosphate (2015) (5)
The Outcomes of Scientific Debates Should Be Published: The Arivale Story. (2020) (5)
Human Kallikrein 3 (prostate-specific antigen) and Human Kallikrein 5 Expression in Salivary Gland Tumors (2006) (5)
Protein Biomarker Discovery (2019) (5)
Intravagal ectopic parathyroid presenting as vocal cord paralysis: case report and review of the literature. (2007) (5)
Kinetic Studies with Ion Selective Electrodes: Determination of Creatinine in Urine with a Picrate Ion Selective Electrode: A Laboratory Experiment. (1983) (5)
Validation of Candidate Protein Biomarkers (2013) (5)
Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. (1999) (5)
New Method for Breast Cancer Diagnosis (1999) (5)
Expression profile of human tissue kallikrein 15 provides preliminary insights into its roles in the prostate and testis. (2018) (5)
Duties and responsibilities of laboratory scientists. (2002) (5)
The obesity epidemic. (2012) (5)
A direct kinetic fluorimetric method for the enzymic determination of lactate in plasma. (1983) (5)
Cancer dynamics and the success of cancer screening programs (2016) (5)
Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment (2021) (5)
A growing phobia (2017) (5)
Kallikrein-mediated activation of PARs in inflammation and nociception (2007) (5)
Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer’s disease (2020) (5)
Reference intervals and biological variation for kallikrein 6: influence of age and renal failure (2012) (5)
Continuous-flow determination of reducing sugars in serum by reaction with periodate ions, with use of a flow-through periodate-sensitive electrode (1983) (5)
Urinary proteomics links keratan sulfate degradation and lysosomal enzymes to early type 1 diabetes (2020) (5)
11 – Detection of Lanthanide Chelates and Multiple Labeling Strategies Based on Time-Resolved Fluorescence (1992) (5)
Automatic determination of ethylene glycol in anti-freeze solutions with a periodate-sensitive flow-through electrode (1980) (5)
The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer. (2009) (5)
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry (2020) (5)
Mining for single nucleotide variants (SNVs) at the kallikrein locus with predicted functional consequences (2014) (5)
The athletes of science (2011) (4)
Theranos revisited: the trial and lessons learned (2021) (4)
Resveratrol, a red wine constituent, has anticarcinogenic properties (2000) (4)
Total Mg2+ measured in serum and urine in the Technicon RA 1000 random access analyzer by use of modified manual calmagite procedure. (1984) (4)
Elevated Estradiol and Testosterone Levels and Risk for Breast Cancer (1999) (4)
Signal amplification in time-resolved fluorometry. (2001) (4)
10 – IMMUNOASSAY CONFIGURATIONS (1996) (4)
12 Kallikrein-related Peptidases and Semen (2012) (4)
24 – DEVELOPMENT OF IN-HOUSE IMMUNOASSAYS (1996) (4)
Semen biomarker TEX101 predicts sperm retrieval success for men with testicular failure (2021) (4)
Mass-spectrometry based assay for targeting fifty-two proteins of brain origin in cerebrospinal fluid. (2020) (4)
Study of the stoichiometry and the kinetics of the Jaffé reaction with a picrate ion-selective electrode (1983) (4)
Evaluation of nonisotopic labeling and detection techniques for nucleic acid hybridization (1993) (4)
Exploring the relationship between serum biomarkers, acute intracerebral changes and outcome after severe traumatic brain injury (TBI) (2013) (4)
Induction of prostate-specific antigen expression by synthetic progestins in patients with prostate and breast cancer. (1998) (4)
Advancing laboratory medicine through innovation: a tale of six inventors. (2012) (4)
Extraction of resveratrol from human blood (1995) (4)
Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women (2017) (4)
Ultrasensitive Time-Resolved Immunofluorometry of Human Albumin in Urine Using Monoclonal Antibodies—A New Assay for Microalbuminuria (1990) (4)
Time-resolved immunofluorometric detection of antigens separated by high-performance liquid chromatography and coated to polystyrene. (1991) (4)
Theranos phenomenon – Part 5: Theranos’ presentation at the American Association for Clinical Chemistry Annual Conference 2016 (2016) (4)
A double monoclonal time-resolved immunofluorometric assay of carcinoembryonic antigen in serum. (1989) (4)
Benefits and harms of wellness initiatives (2019) (4)
A general method for the assay of binders. Application to the potentiometric determination of albumin in human serum, plasma and whole blood. (1986) (4)
Hubris and Sciences (2018) (4)
The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer (2018) (4)
Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition. (2009) (4)
Young scientists and Clinical Biochemists need to develop superior negotiating skills. (2018) (3)
Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers (2015) (3)
16 – Detection of Lanthanide Chelates and Multiple Labeling Strategies Based on Time-Resolved Fluorescence (1995) (3)
Stability of the composite solution [Mercury (II)-TPTZ-iron(II)] used for the automated determination of serum chloride. (1982) (3)
p 53 Gene Mutation , Tumor p 53 Protein Overexpression , and Serum p 53 Autoantibody Generation in Patients with Breast Cancer (2000) (3)
The time of young scientists. (2010) (3)
Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer. (2019) (3)
Novel severe traumatic brain injury blood outcome biomarkers identified with proximity extension assay (2021) (3)
Half-Century of Cancer Biomarkers: Lessons from the Past and Projections for the Future. (2017) (3)
Generation of monoclonal antibodies and development of an immunofluorometric assay for the detection of CUZD1 in tissues and biological fluids. (2017) (3)
Effect of age on serum prostate-specific antigen in women (2017) (3)
Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. (2020) (3)
Direct enzymic fluorimetric method for the determination of individual bile acids in bile. (1983) (3)
Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract (2018) (3)
g-Hydroxybutyrate Concentrations in Pre-and Postmortem Blood and Urine (1998) (3)
Peptidomic Analysis of Urine from Youths with Early Type 1 Diabetes Reveals Novel Bioactivity of Uromodulin Peptides In Vitro. (2020) (3)
Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice (1998) (3)
Continuous-flow potentiometric determination of creatinine in urine with a picrate ion-selective electrode (1982) (3)
Enzymic measurement of primary bile acids and the primary bile acid ratio in serum with the IL-Multistat III Fluorescence Light-Scattering Centrifugal Analyzer. (1984) (3)
Time-resolved fluorescence immunoassay system especially suited for research applications. (1989) (3)
Prognostic value of creatine kinase BB isoenzyme in epithelial ovarian carcinoma. (1995) (3)
Abstract B13: Discovery of novel subtype-specific ovarian cancer biomarkers via integrated tissue proteomics. (2016) (3)
Assay of creatine kinase isoenzyme MB in serum with time-resolved immunofluorometry. (1990) (3)
Determination of the association of urine prostate specific antigen levels with anthropometric variables in children aged 5-14 years. (2010) (3)
Development and evaluation of a competitive time‐resolved immunofluorometric assay for the estrogen‐regulated protein pS2 (1999) (3)
Support staff: Build reward system for ace technicians (2015) (3)
Human kallikrein 5 (hK5): A hovel serum biomarker for ovarian and breast cancer. (2003) (3)
Do Prevotella copri and Blastocystis promote euglycaemia? (2021) (3)
A time-resolved fluoroimmunoassay for alpha-fetoprotein in serum and amniotic fluid (1987) (3)
Highly Sensitive Array Analysis Using Time Resolved Fluorescence and a Novel Streptavidin-Based Reagent (2002) (3)
The First International Symposium on Kallikreins (2006) (3)
Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden (2021) (3)
Cell-free DNA Analysis in Cancer. (2019) (3)
Time-resolved immunofluorometric assay for thyroxine-binding globulin in serum. (1989) (3)
Development and Evaluation of a Competitive Time-Resolved Immunofluorometric Assay for the Estrogen-Regulated Protein pS 2 (1999) (3)
An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays (2007) (3)
Getting noticed is half the battle. (2015) (3)
I detected my cancer with my smart phone. (2011) (2)
Prevalence of antibodies against p53 protein in various cancers (1993) (2)
Kallikrein-related peptidase expression in odontogenic cysts and tumors: An immunohistochemical comparative study. (2017) (2)
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer (2004) (2)
Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line (2022) (2)
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia (2021) (2)
Theranos: Almost Complete Absence of Laboratory Medicine Input. (2019) (2)
Re: The clinical usefulness of prostate specific antigen: update 1994. (1996) (2)
Wellness Initiatives: Benefits and Limitations. (2017) (2)
Time-resolved immunofluorometry of follitropin in serum. (1989) (2)
Proteomic and genomic technologies for biomarker discovery (2006) (2)
Kallikrein-related Peptidase 13 (2013) (2)
Amplification of human genomic DNA sequences with polymerase chain reaction using a single oligonucleotide primer (1999) (2)
Potentiometric measurements in air-segmented streams without debubbling (1989) (2)
The roles of proteases in prostate cancer (2023) (2)
Plasma Protein Profiling by Proximity Extension Assay Technology Reveals Novel Biomarkers of Traumatic Brain Injury-A Pilot Study. (2021) (2)
Prostaglandin D synthase does not produce prostate-specific antigen cross-reactivity in renal cell carcinoma. (2001) (2)
Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection (2022) (2)
and TEX 101 Quantified in Seminal Plasma Differential Diagnosis of Azoospermia with Proteomic Biomarkers ECM 1 (2013) (2)
Determination of the second ionization constant of 3,5-dinitrosalicylic acid (DNSH2) and the instability constant of [DNSFe]+ and titrimetric determination of thiourea with a 3,5-dinitrosalicylate-selective electrode (1986) (2)
Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden (2020) (2)
Clinical application of ultrasensitive prostate-specific antigen assays. (1997) (2)
Multi-omics biomarker pipeline reveals elevated levels of protein-glutamine gamma-glutamyltransferase 4 in seminal plasma of patients with prostate cancer (2017) (2)
The milk of lactating women contains prostate specific antigen (1995) (2)
Can chemoprevention reduce the risk of prostate cancer? (2010) (2)
The growing problem of predatory publishing: a case report (2019) (2)
Significant increase of serum prostate-specific antigen after exercise (2016) (2)
Human Kal l ikre in 6 ( hK 6 ) : A New Potent ia l Serum Biomarker for Diagnosis and Prognosis of Ovar ian Carc inoma (2003) (2)
Cancer Screening Companies Are Rapidly Proliferating: Are They Ready for Business? (2022) (2)
EPCA-2: a highly specific serum marker for prostate cancer. (2012) (2)
New Nomenclature for the Human Tissue Kallikrein (2000) (2)
Rofa Nadofederal-The greatest tennis player that ever lived: A science fiction story depicting a future where biotechnology is unchecked. (2017) (2)
Cortisol assay in serum with competitive immunoassay and time-resolved fluorescence spectroscopy (1987) (2)
Mitochondrial Genome Deletion Aids in the Identification of Both False and True Negative Prostate Needle Core Biopsies (2008) (2)
Fluorescence spectroscopy : Clinical chemistry (1993) (1)
Evaluation of Sieve as a Label-Free Mass Spectrometry Protein Quantification Method (2009) (1)
Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry (2012) (1)
COVID-19 and the Le Chatelier’s principle (2021) (1)
Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome (2013) (1)
COMMENT ON: THE CLINICAL USEFULNESS OF PROSTATE SPECIFIC ANTIGEN : UPDATE 1994. AUTHORS' REPLY (1996) (1)
Natriuretic Peptides in Heart Failure Moderators : (2014) (1)
Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA (2021) (1)
Comment on: Diagnostic potential of serum proteomic patterns in prostate cancer by Diamandis. Author'reply (2004) (1)
Kallikrein Protease Involvement in Skin Pathologies Supports a New View of the Origin of Inflamed Itchy Skin (2011) (1)
Is it time to abandon the Nobel Prize? (2018) (1)
A replacement for the testosterone “sex gap” (2016) (1)
Human Tissue Kallikrein 10 (2013) (1)
Lost in (the Business of) Translation: Invest in the Youth (2006) (1)
Playing the game of scientific publishing. (2019) (1)
Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. (2018) (1)
Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer (2020) (1)
Athletes beware before throwing towels to audiences (2017) (1)
Putative Concussion Biomarkers Identified in Adolescent Male Athletes Using Targeted Plasma Proteomics (2021) (1)
Assay requirements for COVID-19 testing: serology vs. rapid antigen tests (2021) (1)
Identification of TEX101 functional interactome through proteomic measurement of human spermatozoa homozygous for the missense variant rs35033974 (2018) (1)
3.P.43 Identifying the major phenolic antioxidants of wine (1997) (1)
Determination of human chorionic gonadotropin by a time-resolved immunofluorometric assay (1987) (1)
From the amyloid hypothesis to the autoimmune hypothesis of Alzheimer’s disease (2021) (1)
The question I hate the most (2016) (1)
Application of Modular Therapy for Renoprotection in Experimental Chronic Kidney Disease. (2015) (1)
Kallikrein-Related Peptidases: An Emerging Family of Pivotal Players in Epidermal Desquamation and Barrier Function (2009) (1)
Automated determination of crude protein, phosphorus, calcium, iron, and magnesium in feeds by using stopped-flow analyzer. (1983) (1)
Babesia microti-induced fulminant sepsis in an immunocompromised host: A case report and the case-specific literature review (2022) (1)
Highlight: The 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (2014) (1)
Deciphering the ovarian cancer ascites fluid peptidome (2014) (1)
Characterization of the BRCA1-like immunoreactivity of human seminal plasma. (1999) (1)
Inappropriate extrapolations abound in fecal microbiota research (2021) (1)
Can post‐treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer? (2020) (1)
The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology (2022) (1)
Abstract 538: Identification and validation of novel prostate cancer biomarkers using the Berg Interrogative Biology™ platform (2015) (1)
Biomarkers, assays, and therapies for Alzheimer disease. (2015) (1)
Lifestyle Modification Is Appropriate as Primary Prevention. (2021) (1)
A possible association between fetal abnormalities and levels of prostate specific antigen in amniotic fluid (1995) (1)
Unveiling the Right Side: How to Win Wimbledon Championships: Creating Beklof and Vamos (2009) (1)
Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens (2022) (1)
Fragment analysis of the p53 gene in ovarian tumors. (1998) (1)
P4 medicine or O4 medicine? The perils of population wide, asymptomatic disease screening. (2020) (1)
Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry (2014) (1)
Delineating the Secretome of Eleven Breast Cell Lines in the Quest for Novel Breast Cancer Biomarkers. (2009) (1)
8 assay of albumin in serum based on specific ion-bindingand ion-selective electrode (ISE) potentiometry (1985) (1)
The new human kallikrein gene family on chromosome 19Q13.3–Q13.4 and association to various tumours (2000) (1)
MP008SILAC-BASED PROTEOMICS OF PRIMARY HUMAN RENAL CELLS REVEALS A NOVEL LINK BETWEEN MALE SEX HORMONES AND IMPAIRED ENERGY METABOLISM IN DIABETIC KIDNEY DISEASE (2016) (1)
8 Expression of Kallikrein-related Peptidases under (Patho-)Physiological Conditions (2012) (1)
Determination of serum creatinine by liquid chromatography isotope dilution tandem mass spectrometry (LC–IDMS/MS): A candidate reference method (2008) (1)
p21WAF1 protein expression determined by quantitative immunoassay in relation to non-small-cell lung cancer aggressiveness (2000) (1)
Single Nucleot ide Polymorphism of the Human Kal l ikre in-2 Gene Highly Corre lates With Serum Human Kal l ikre in-2 Leve ls and in Combinat ion Enhances Prostate Cancer Detect ion (2003) (1)
TIME-RESOLVED FLUOROMETRY WITH LANTHANIDE CHELATES AS LABELS-PRINCIPLES, APPLICATIONS AND NEW DEVELOPMENTS (1991) (1)
A new method for early cancer detection based on platelet transcriptomics will have low positive predictive value (2022) (1)
The Quest for Renal Disease Proteomic Signatures: Where Should We Look? (2010) (1)
Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics (2018) (1)
A Key to Success Is the Key that Opens and Closes the Lab Door. (2019) (1)
MC-1 A new generation of time-resolved fluoroimmunoassays with europium chelates as labels (1988) (1)
Abstract LB-293: High-throughput proteomic analysis identifies protein s as a modulator of high grade and castrate-resistant prostate cancer (2012) (1)
Fibrinolytics, enzyme inhibitors, and cancer survival (2009) (1)
IMMUNOFLUOROMETRICALLY DETERMINED p 53 ACCUMULATION AS A PROGNOSTIC INDICATOR IN ITALIAN BREAST CANCER PATIENTS (1998) (1)
1 Genomic Structure of the KLK Locus (2012) (1)
Abstract 3826: Clinical validation of a serum protein panel (FLNA, FLNB and KRT19) for diagnosis and prognosis of prostate cancer (2017) (1)
[Human kallikreins as tumor markers. Validation of potential marker of prostate cancer in serum and tissue]. (2007) (1)
Ultrasensitivedetection of prostate-specific antigenby a time-resolved immunofluorometric assayand the Immulite immunochemiluminescent third-generationassay:potential applicationsin prostate and breast cancers (1996) (1)
Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up. (2020) (1)
The mother of all battles: Viruses vs humans. Can humans avoid extinction in 50–100 years? (2022) (1)
Prostase/KLK-L1 is differentially expressed in normal/benign versus malignant ovarian tissues (2000) (1)
Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation (2023) (1)
105 HIGH EXPRESSION LEVELS OF THE HUMAN KALLIKREIN-LIKE PEPTIDASES KLK14 AND KLK 15 IN PROSTATIC ADENOCARCINOMA ARE ASSOCIATED WITH ELEVATED RISK OF PROSTATE-SPECIFIC ANTIGEN RELAPSE (2007) (1)
Kallikrein 6 as a biomarker for the detection of metastatic cancer cells in blood of ovarian cancer patients (2004) (0)
Protect Your Fibroblasts Before They Become Gametes (2022) (0)
Serum H uman G landular K allikrein-2 P rotease L evels Predict t he P resence o f P rostate C ancer A mong M en W ith Elevated P rostate-Specifi c A ntigen (2000) (0)
Abstract 1570: Early Detection Research Network (EDRN) validation of circulating ovarian cancer biomarkers (2015) (0)
Tumour-derived proteinases and signalling: kallikrein-mediated PAR activation and inflammation. (2007) (0)
Cloning of a human gene, encoding a member of the Ser/Arg-rich family of proteins that interact with RNA Pol-II (2000) (0)
Anti-androgen activity of flavonoids (2000) (0)
Research forever – Klaus Jung (2013) (0)
Convoluted molecular maze of neprilysin (2022) (0)
A Conversation Between Two Viruses: SARS-CoV and SARS-CoV-2 — Based on a True Story (2020) (0)
KLK5 (Kallikrein-related peptidase 5) (2011) (0)
Introduction to the Special Collection-Beating Cancer with Early Detection: A Seasoned Idea with New Insights. (2018) (0)
Abstract C47: Quantitative mass spectrometry reveals that enzymes of the ketogenic pathway are upregulated during high-grade prostate cancer (2012) (0)
Abstract B61: Proteomic profiling of ovarian cancer and mesothelial cells reveals novel mediators implicated in the metastatic progression of ovarian cancer to the peritoneum (2013) (0)
Two adhesion molecules: New serological diagnostic breast cancer biomarkers (2008) (0)
Quantitative polymerase chain reaction analysis of pathogenic DNA sequence using an internal DNA sequence standard constructed by recombinant DNA methodology (1993) (0)
1510 ACCURACY OF TESTOSTERONE CONCENTRATIONS IN COMPOUNDED TESTOSTERONE PRODUCTS (2013) (0)
HUMAN KALLIKREINS AS NOVEL SERUM BIOMARKERS IN EPITHELIAL OVARIAN CANCER (2004) (0)
Down-Regulationof theHumanKallikreinGene 5 ( KLK 5 ) in ProstateCancerTissues (2002) (0)
Prostate specific antigen gene expression in ovarian cancer post-liver transplantation (1995) (0)
From Camille Nούς to Apollonian and the Dionysian scientists (2021) (0)
Prostaglandin D2 synthase in amniotic fluid and maternal serum: Possible association with fetal abnormalities (1996) (0)
44PUNRAVELLING THE EFFECT OF ESTROGEN ON BREAST CANCER CELL PROTEOME USING QUANTITATIVE PROTEOMICS (2013) (0)
Please do not call it Theranos (2023) (0)
P919. Subfractions of prostate specific antigen differ in serum of normal women and women with malignant and benign breast diseases (1997) (0)
Correction to: A proteome-wide immuno-mass spectrometric identification of serum autoantibodies (2019) (0)
815: Human Kallikrein 2 (HK2) Inhibitors Suppress Tumor Growth of Prostate Cancer Xenografts in Nude Mice (2006) (0)
The plasma peptidome (2018) (0)
PP11 Expression differences of proteolytic factors uPA, PAI-1, and seven kallikrein-related peptidases (KLK5, 6, 7, 8, 10, 11, 13) between primary tumor and omentum metastasis impact outcome in advanced ovarian cancer (2009) (0)
Beyond the amyloid hypothesis: how current research implicates autoimmunity in Alzheimer's disease pathogenesis. (2023) (0)
Playing the Trumpet (2011) (0)
A new enzyme-linked immunosorbent assay (ELISA) for human free and bound kallikrein 9 (2017) (0)
PROCEDURE, REAGENTS AND KIT FOR THE DIAGNOSIS AND TARGETED FOR SIEBTESTUNG p53 MÜTATIONEN (1995) (0)
Abstract 4870: High-throughput proteomics using stable isotope labelling with amino acids in cell culture (SILAC) reveals potential modulators of androgen-independent prostate cancers (2011) (0)
Modelsof Neoplasiaand Their DiagnosticImplications: A HistoricalPerspective (1993) (0)
Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues (2000) (0)
Abstract P6-05-09: Unravelling the global effect of estrogen on breast cancer cell proteome using quantitative proteomics. (2012) (0)
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease (2018) (0)
Analysis of the Human Kallikrein Gene Locus dentifies a Unique Polymorphic Minisatellite Element (2001) (0)
Discovery of novel glioma serum biomarkers by proximity extension assay (2023) (0)
Subject Index Vol. 26, 2005 (2005) (0)
Scientific Journals Should Encourage, Not Hinder, Debates About Their Published Papers (2023) (0)
Prognostic V alue o f t he H uman K allikrein G ene 1 5 E xpression in O varian C ancer (2003) (0)
The Prostate 54 : 220 ^ 229 ( 2003 ) SerumHumanGlandularKallikrein ( hK 2 ) and Insulin-LikeGrowth Factor 1 ( IGF-1 ) Improve theDiscriminationBetweenProstateCancer andBenign ProstaticHyperplasia in CombinationWithTotaland % Free PSA (2002) (0)
Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay (2023) (0)
Contents Vol. 26, 2005 (2005) (0)
CRISPR-Cas 9 System : Opportunities and Concerns Moderators : (2016) (0)
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study (2022) (0)
The International Society for Enzymology: a glorious history, a golden legacy (2018) (0)
Abstract 4574: Mining the proteome of breast cancer cell lines and nipple aspirate fluid in the quest for novel breast cancer biomarkers (2010) (0)
Abstract 5103: Mining the pancreatic cancer ascites fluid proteome with mass spectrometry (2011) (0)
Invited critical review Human tissue kallikreins: A road under construction (2007) (0)
Abstract A20: Integrating high-throughput technologies for the identification and validation of ovarian cancer biomarkers (2013) (0)
Subject Index Vol. 25, 2004 (2004) (0)
New methodology for measuring anti-p53 antibodies in human serum (1993) (0)
Prognostic significance of multiple kallikreins in high-grade astrocytoma (2015) (0)
Do you think an ideal biomarker for rapid and reliable diagnosis of AMI is still lacking ? What are some of the challenges with the current pantheon of MI testing approaches used today ? (2013) (0)
Human Tissue Kallikrein (KLK) Expression and IMRT Response in Intermediate Risk Prostate Cancer (2011) (0)
Solid-state extraction of digoxin-like substancesfrom human urine (1985) (0)
543 Methylation of Kallikrein-related peptidases as novel diagnostic and prognostic biomarkers for prostate cancer (2012) (0)
Human kallikreins Gene discovery and clinical applications in cancer (2002) (0)
P-655: Seminal plasma lipocalin type PGDS: A new marker for obstructive azoospermia (2006) (0)
Labelling strategies in time-resolved fluoroimmunoassays and immunofluorometric assays (1987) (0)
Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract. (2018) (0)
Proteolytic cascades of human tissue kallikreins (2006) (0)
Association between different pathologies and cancer , based on epidemiologic and experimental studies (2013) (0)
The plasma peptides of breast versus ovarian cancer (2019) (0)
The plasma peptides of ovarian cancer (2018) (0)
Re : Induced Abortion and Risk for Breast Cancer : Reporting ( Recall ) Bias in a Dutch Case – Control Study (1997) (0)
How I first met Dr. Morton K. Schwartz (2017) (0)
CHARACTERIZATION OF THE BRCA 1-LIKE IMMUNOREACTIVITY OF HUMAN SEMINAL PLASMA (1999) (0)
A time-resolved fluoroimmunoassay for ferritin in serum (1987) (0)
Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry (2019) (0)
Human K allikrein 6 ( hK6): A N ew P otential S erum B iomarker for D iagnosis a nd P rognosis o f O varian C arcinoma (2003) (0)
Responses by Kallikrein-Related Peptidase Induction of Complement C 3 a Receptor Ricklin and (2013) (0)
Colorectal carcinoma elicits a humoral immune response against P53 mutant protein (1994) (0)
Abstract P2-05-11: Proteomic identification and in-silico verification of subtype-specific signatures in breast cancer. (2012) (0)
Reflection on the Discovery of Carcinoembryonic Antigen , Prostate-Specific Antigen , and Cancer Antigens CA 125 and CA 19-9 Moderator : (2012) (0)
Serum p53 autoantibodies: incidence in ovarian carcinoma (1995) (0)
T142 Role of kallikrein 6 (KLK6) in the differential diagnosis of dementia (2013) (0)
Abstract B1: Validation of a panel of candidate pancreatic cancer serum biomarkers identifies SYCN and REG1B to significantly improve the performance of CA19.9. (2012) (0)
The Science of Man in Ancient Greece. Maria Michela Sassi. Chicago and London: The University of Chicago Press, 2001, 254 pp., $34.00, hardcover. ISBN 0-226-73530-3. (2002) (0)
1623: Seminal Plasma Upocalin Type Pgds: A Potential Marker for the Diagnosis of Obstructive Azoospermia (2006) (0)
ProteomicSignaturesofAngiogenesisinAndrogen- Independent Prostate Cancer (2013) (0)
Abstract 5105: Towards a multiparametric biomarker panel for pancreatic cancer detection (2011) (0)
Quantitative analysis of polymerase chain reaction products with high performance liquid chromatography and fluorometric detection (1993) (0)
Designing of immunogenic peptides from Dengue Virus NS1 region for production of monoclonal antibodies as diagnostic intermediates (2015) (0)
Driving on a highway to hell I found the stairway to heaven. A mentorship lecture intermixed with rock music and a quiz (2019) (0)
Abstract LB-282: Cancer-specific motogenic signals induce collective migratory pattern in myofibroblasts via increased tight junction formation (2011) (0)
Identification and characterization of an antibody-bound thyroid-stimulating hormone (TSH) with differential effects on various clinically available serum TSH assays (2012) (0)
Androgens, progestins and tamoxifen induce PSA production in the breast cancer cell line T-47D (1994) (0)
S20 Novel biomarkers for prognosis and therapy response in ovarian cancer (2007) (0)
MP16-12 CORRELATION OF PROSTATIC HISTOLOGICAL INFLAMMATION CHARACTERIZED BY TYPE AND SITE WITH PROSTATE SPECIFIC ANTIGEN VALUES IN MEN WITH BENIGN FINDINGS ON PROSTATE BIOPSY (2014) (0)
Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring (2016) (0)
Continuous-flow potentiometric determination of α-amylase activity in serum and urine (1985) (0)
KLK11 (Kallikrein-related peptidase 11) (2011) (0)
A proteome-wide immuno-mass spectrometric identification of serum autoantibodies (2019) (0)
Differential Expressionof theHumanKallikreinGene 14 ( KLK 14 ) inNormalandCancerous ProstaticTissues (2003) (0)
Mass spectrometry as a cancer diagnostic tool: a meta-analysis of published data (2005) (0)
Prognostic and predictive value of P53/WAF‐1 expression in epithelial ovarian cancer (2000) (0)
Subject Index Vol. 24, 2003 (2004) (0)
Abstract 4560: Integrative proteomic profiling of pancreatic cancer cell line supernatants, pancreatic juice and ascites fluid for the identification of novel pancreatic cancer biomarkers (2010) (0)
ID: 119 Effects of overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 on the malignant phenotype of ovarian cancer cells (2006) (0)
A candidate new gene on human chromosome 5q12 contains a motif that is found in transcriptional co-activators. (1998) (0)
Nouveau gene kallikreine (2001) (0)
HumanKallikrein-Related Peptidase 12 : AntibodyGeneration and Immunohistochemical Localization in ProstaticTissues (2007) (0)
Learning from Siddhartha. (2014) (0)
Abstract 2256: Identifying the molecular signature of melanoma metastasis via a personalized quantitative proteomics approach (2010) (0)
Human tissue kallikreins : The cancer biomarker family q (2007) (0)
Perspective: Audacity is Overrated (2010) (0)
PROSTAGLANDIN D SYNTHASE IN HUMAN SEMEN: A MARKER TO DIFFERENTIATE OBSTRUCTIVE FROM NON-OBSTRUCTIVE AZOOSPERMIA (1999) (0)
loning and Molecular Characterization of Two Splice ariants of a New Putative Member of the Siglec-3-like ubgroup of Siglecs (2001) (0)
Abstract 2223: ELISA coupled anion exchange methodology for separation of KLK6 glycoprotein subpopulations in biological fluids (2011) (0)
Association between breast cancer patient survival and levels of creatine kinase BB in tumor cytosols (1995) (0)
Multiplex Proteomics for the Identification of Protein Biomarkers Predictive of Acute Graft-Versus-Host Disease (GVHD) in Allogeneic Hematopoietic Cell Transplantation (HCT) (2022) (0)
Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer (2019) (0)
Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9 (2013) (0)
Relationships between mutant P53 protein overexpression and other prognostic indicators in breast cancer (1995) (0)
A highly sensitive alpha-fetoprotein (AFP) immunoassay based on enzymatically amplified time-resolved fluorometry (1993) (0)
Quantitative analysis of prostate specific antigen and mutant P53 protein in breast tumor cytosols: Relationships with other prognostic indicators (1994) (0)
206 Fine-mapping of the Kallikrein region and its role in prostate cancer aggressiveness: Results from a Canadian cohort and the European Randomized Study for Prostate Cancer Screening (2014) (0)
Abstract PR03: Immuno-mass spectrometric identification of serum biomarkers of response and toxicity to pembrolizumab (2020) (0)
Poem: Waiting for the barbarian Corona viruses (2020) (0)
Is resveratrol the soluti on to the French Paradox (1994) (0)
Breast Cancer Human Kallikrein 14 : A New Potential Biomarker for Ovarian Updated (2003) (0)
Abstract A3: Validation of candidate serum biomarkers demonstrates the potential of CUZD1 and LAMC2 to complement CA19.9 for pancreatic cancer diagnosis. (2012) (0)
2038 DIFFERENTIAL DIAGNOSIS OF AZOOSPERMIA WITH PROTEOMIC BIOMARKERS QUANTIFIED IN SEMINAL PLASMA (2013) (0)
Abstract 4923: Myofibroblasts induce specific epithelial-to-mesenchymal transition (EMT) patterns in colorectal cancer cells by enhanced secretion of bone morphogenic protein (BMP) inhibitors (2011) (0)
Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line (2022) (0)
Advocate cultivation of academic ethics: why is it necessary? (2019) (0)
Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas (2016) (0)
Abstract 5144: Exploring the potential of a novel multiplex proteomics technology to identify personalized biomarkers of tumor burden in ovarian cancer patients (2020) (0)
Tumor microenvironment-released peptides: could they form the basis for an early-diagnosis breast cancer test? (2014) (0)
Contents Vol. 24, 2003 (2004) (0)
Identification of immunoreactive antigens in ovarian and breast carcinoma (2001) (0)
CHAPTER 12:Discovery and Validation Case Studies, Recommendations: Bottlenecks in Biomarker Discovery and Validation by Using Proteomic Technologies (2013) (0)
Contents Vol. 25, 2004 (2004) (0)
Early cancer detection by a targeted methylation assay of circulating tumor DNA in plasma (2022) (0)
Is Hormonally Regulated andGene Family , Is Expressed in Prostate and Breast Tissues , Is a New Member of the Human Kallikrein KLK-L 1 Prostase (1999) (0)
Immunohistochemical expression of human tissue kallikreins in neoplasms of various organs (2006) (0)
Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer (2017) (0)
Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET (2019) (0)
HUMAN KALLIKREIN 2 (HK2) INHIBITORS SUPPRESS TUMOUR GROWTH OF PROSTATE CANCER XENOGRAFTS IN NUDE MICE (2006) (0)
Level differentials of proteolytic factors uPA, PAI-1 and human kallikreins (hK) 5,6,7,8,10,11,13 in primary ovarian carcinoma tissues and corresponding omentum metastases impact on disease outcome (2005) (0)
Retrieval of autoantibodies from ovarian cancer cells present in ascites fluid (2005) (0)
Impact of proteolytic factors on surgical success and survival in ovarian cancer (2005) (0)
Featuring the Special Issue Editors Dr. Kenneth R. Evans, Dr. Barry R. Hoffman and Dr. Eleftherios P. Diamandis (2007) (0)
Abstract B21: Epigenetic and post-transcriptional regulation of the kallikrein gene family as a novel panel of prostate cancer biomarkers (2013) (0)
Exploring the extracellular transcriptome in seminal plasma for non-invasive prostate cancer diagnosis (2021) (0)
Impact of proteolytic factors (uPA, PAI-I, tissue kallikreins) on surgical success and survival in ovarian cancer (2005) (0)
Discovery of a human testis-specific protein complex TEX101-DPEP3 and selection of its disrupting antibodies (2018) (0)
Resveratrol and ethanol as mediators of changes in plasma lipids and lipoproteins (1994) (0)
Creatine kinase isoenzyme BB is associated with the estrogen receptor in breast cancer (1994) (0)
Cloning and characterization of novel isoforms of the human kallikrein 6 gene q , qq , w (2004) (0)
Human kallikrin 6 (hK6) and 10 (hK10): new potential serum biomarkers for diagnosis and prognosis of epithelial ovarian cancer (2002) (0)
MP49-20 FINE-MAPPING OF THE KALLIKREIN REGION AND ITS ROLE IN PROSTATE CANCER AGGRESSIVENESS: RESULTS FROM A CANADIAN COHORT AND THE EUROPEAN RANDOMIZED STUDY FOR PROSTATE CANCER SCREENING (2014) (0)
Prostate-Specific Antigen and Female Breast Cancer-Revisited. (2023) (0)
Dramatic overexpression of the Kallikrein-like gene 2 (KLK-L2), in ovarian carcinomas (2000) (0)
Single N ucleotide P olymorphism o f t he H uman K allikrein-2 Gene H ighly C orrelates W ith S erum H uman K allikrein-2 Levels a nd i n C ombination E nhances P rostate Cancer D etection (2003) (0)
News Stories and Medical Breakthroughs. (2020) (0)
Dinucleotide repeat length polymorphism on the 3 untranslated region of the SRD5A2 gene in breast cancer (2001) (0)
Prognostic impact of kallikrein-related peptidase transcript levels in prostate cancer. (2023) (0)
9 Genomic Instability of the KLK-locus in Cancer (2012) (0)
Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis (2007) (0)
HUMAN KALLIKREIN GENE 15 (KLK15) EXPRESSION (2003) (0)
The significance of prostate specific antigen (PSA) in breast cancer (1998) (0)
GERMLINE MUTATIONS IN THE KALLIKREIN 6 REGION AND PREDISPOSITION FOR AGGRESSIVE PROSTATE CANCER: PD65‐01 (2017) (0)
Abstract 4573: Discovery of candidate biomarkers for colorectal cancer using mass spectrometry-based proteomic analysis of cell line conditioned media (2010) (0)
New Kallikrein markers for ovarian cancers (2009) (0)
Time-resolved enzyme immunoassay for the determination of thyrotropin in serum (1993) (0)
Development of an immunofluorometric assay for human kallikrein 14 Preliminary clinical applications (2003) (0)
Prognost ic Value of the Human Kal l ikre in Gene 15 Express ion in Ovar ian Cancer (2003) (0)
Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains (2013) (0)
TISSUE HUMAN KALLIKREIN 11 (HK11) EVALUATION (2003) (0)
My scientific genealogy and the Toronto ACDC Laboratory, 1988–2022 (2022) (0)
Wellness Initiatives: Beneﬁts and Limitations (2017) (0)
Abstract 3037: Integrated Genomic, MicroRNA (miRNA) and Proteomic Profiling of Ovarian Carcinoma for Biomarker Discovery (2010) (0)
Coordinated hormone regulation of multiple kallikreins in breast cancer cell lines (2006) (0)
CEBP FOCUS Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA A C (2020) (0)
Time to reflect (2013) (0)
B7-H4 (DD-O110) protein is over-expressed in early-stage ovarian cancer tumor tissue (2006) (0)
Production of polyclonal and monoclonal antibodies against human tissue kallikrein 12 (2004) (0)
Production of the extracellular domain of Siglec-9 using and an E.coli expression system and generation of anti-Siglec-9 antibodies (2005) (0)
Drabovich 1..10 (2013) (0)
HUMAN KALLIKREINS (HKS) AS NOVEL SERUM BIOMARKERS IN OVARIAN CANCER (2003) (0)
Prognostic value of immunofluorometrically quantifed P53 protein in ovarian carcinoma (1995) (0)
Abstract 1168: Integrated genomic, microRNA (miRNA) and proteomic profiling by stable isotope labeling with amino acids in cell culture (SILAC) of ovarian carcinoma for biomarker discovery (2011) (0)
Commensals can become pathobionts. (2021) (0)
Controlled COVID-19 Infection in Hospitals Could Achieve A Safer Exit Strategy in the Near-Term: Assessing Risks and Benefits (2020) (0)
Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: potential to complement CA125 in detecting non-serous subtypes (2022) (0)
Potential risks in fecal microbiota transplantation (2019) (0)
Unveiling the Right Side: A Conversation with Pheidias and Pericles about the Elgin Marbles and Other Matters (2010) (0)
KLK10 (kallikrein-related peptidase 10) (2011) (0)
To Screen or Not to Screen (2006) (0)
Proteomic Analysis of a Rodent Model of Heart Failure With Preserved Ejection Fraction - the Goto Kakizaki Rat (2013) (0)
The diagnostic and prognostic value of 2 novel serum tumor markers human kallikrein 6 (hK6) and 10 (hK10) in epithelial ovarian cancer (2002) (0)
Comparative proteomics of ovarian cancer spheroid formation reveals an increased expression of calcium-activated chloride channel regulator 1 (2015) (0)
Assessment of serum prostate specific antigen (2004) (0)
Detection of SERUM testosterone by liquid chromatography–isotope dilution tandem mass spectrometry (2008) (0)
Dr. Lee Goodglick: A Valuable Collaborator and A Dear Friend (2015) (0)
Use of a sintered glass crucible for easy construction of liquid-membrane ion-selective electrodes (1988) (0)
Structural characterization of the prostate specific antigen gene from breast tumors and cell lines (1997) (0)
Author response: Stable flow-induced expression of KLK10 inhibits endothelial inflammation and atherosclerosis (2021) (0)
Sensitive Serology Measurements in the Saliva of Individuals with COVID-19 Symptoms Using a Multiplexed Immunoassay (2022) (0)
The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass (2014) (0)
Abstract 4916: Molecular basis for the concentration-dependent tumor suppressing effects of KLK6 in breast cancer (2012) (0)
Cloning of a Novel Human Gene on hromosome 4 p 11 by Immunoscreening f an Ovarian Carcinoma cDNA Library (2001) (0)
The Prostate ThreeNewSerumMarkers for ProstateCancer DetectionWithin a Percent Free PSA-Based ArtificialNeuralNetwork (2005) (0)
A Day in the Life of Dr. Bean and How the NIH Is Wasting $20 Billion per Year. (2015) (0)
Abstract LB-332: High-throughput proteomic analysis identifies protein S as a potential modulator of androgen-independent prostate cancer (2011) (0)
Focus on technical advances (2002) (0)
Advocate cultivation of academic ethics: why is it necessary? (2020) (0)
Prostate cancer screening using prostate specific antigen extracted from dried blood on filter paper (1995) (0)
Deciphering the peptidome of urine from ovarian cancer patients and healthy controls (2014) (0)
Human kallikrein 6 (kH6): A potential serum tumor marker for diagnosis and prognosis of ovarian cancer (2002) (0)
A quantitative proteomic approach to identify key mediators of cancer progression in “tumor-host cell interaction” model systems (2010) (0)

This paper list is powered by the following services:

Other Resources About Eleftherios Diamandis

en.wikipedia.org

What Schools Are Affiliated With Eleftherios Diamandis?

Eleftherios Diamandis is affiliated with the following schools:

Eleftherios Diamandis's Academic­Influence.com Rankings

Why Is Eleftherios Diamandis Influential?

Eleftherios Diamandis's Published Works

Published Works

Other Resources About Eleftherios Diamandis

What Schools Are Affiliated With Eleftherios Diamandis?

Eleftherios Diamandis's AcademicInfluence.com Rankings